Skip to main content

Table 7 Relationship between pathological findings or renal outcome and use of MMF/CYC

From: Comparison of the 2018 and 2003 International Society of Nephrology/Renal Pathology Society classification in terms of renal prognosis in patients of lupus nephritis: a retrospective cohort study

 

MMF/CYC (+)

MMF/CYC (−)

p value

Class, n (%)

  

< 0.01a

 III

8 (18.2)

36 (82.0)

 

 IV

16 (45.7)

19 (54.3)

 

 III/IV+V

8 (16.0)

42 (84.0)

 

Activity index, median (IQR)

6 (4, 9)

3 (2, 6)

0.02b

Chronicity index, median (IQR)

4 (2, 4)

3 (1, 4)

0.26b

eGFR 30% decline, n (%)

5 (15.6)

31 (30.7)

0.15c

  1. IQR interquartile range, MMF mycophenolate mofetil, CYC cyclophosphamide
  2. aPearson’s chi-square test
  3. bMann–Whitney U test
  4. cLog-rank test
Back to article page

Arthritis Research & Therapy

ISSN: 1478-6362

Contact us